![](https://news.europawire.eu/wp-content/uploads/2014/01/sandoz.jpg)
The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the confirmatory clinical safety and efficacy study compares originator etanercept to a biosimilar candidate … Read the full press release